carvedilol

Known as: (+-)-1-(Carbazol-4-yloxy)-3-((2-(O-methoxyphenoxy)ethyl)amino)-2-propanol, Carvedilolum, carvedilol [Chemical/Ingredient] 
A synthetic antihypertensive methoxyphenoxy- 2-propanol derivative with no intrinsic sympathomimetic activity, Carvedilol acts as a nonselective beta… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1984-2018
05010015019842018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
OBJECTIVES The aim of this study was to determine the protective effect of carvedilol in anthracycline (ANT)-induced… (More)
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
CONTEXT Beta-blockers have been shown to decrease cardiovascular risk in patients with hypertension and type 2 diabetes mellitus… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2003
Highly Cited
2003
BACKGROUND Beta blockers reduce mortality in patients who have chronic heart failure, systolic dysfunction, and are on background… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2002
Highly Cited
2002
BACKGROUND Beta-blocking agents improve functional status and reduce morbidity in mild-to-moderate heart failure, but it is not… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
Highly Cited
2001
Highly Cited
2001
BACKGROUND Beta-blocking agents reduce the risk of hospitalization and death in patients with mild-to-moderate heart failure, but… (More)
Is this relevant?
Highly Cited
1997
Highly Cited
1997
OBJECTIVES The aim of this study, a substudy of the Australia-New Zealand trial of carvedilol in patients with heart failure due… (More)
  • table 1
  • table 2
  • figure 2
  • figure 1
Is this relevant?
Highly Cited
1996
Highly Cited
1996
BACKGROUND Controlled clinical trials have shown that beta-blockers can produce hemodynamic and symptomatic improvement in… (More)
Is this relevant?
Highly Cited
1996
Highly Cited
1996
BACKGROUND We tested the hypothesis that carvedilol inhibits clinical progression in patients with mildly symptomatic heart… (More)
Is this relevant?
Highly Cited
1996
Highly Cited
1996
BACKGROUND We conducted a multicenter, placebo-controlled trial designed to establish the efficacy and safety of carvedilol, a… (More)
Is this relevant?
Highly Cited
1996
Highly Cited
1996
BACKGROUND Carvedilol has improved the symptomatic status of patients with moderate to severe heart failure in single-center… (More)
Is this relevant?